Injectable Crosslinked Hyaluronic Acid–DNA Composition for Enzyme Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional hyaluronic acid-based fillers lack functional composites with skin regeneration effects and are prone to enzyme degradation due to the use of non-crosslinked hyaluronic acid.
Innovation Solution
A hyaluronic acid composition is developed by mixing crosslinked hyaluronic acid derivatives with DNA fractions, specifically polynucleotide (PN) or polydeoxyribonucleotide (PDRN), at a weight ratio of 7.0 to 9.5:0.5 to 3.0, to enhance viscoelasticity and resistance to hyaluronidase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If non-crosslinked hyaluronic acid is used to prepare filler products, then good feeling during operation is achieved, but the product is easily degraded by enzyme reaction
Solution Approach 1:
The patent creates a composite filler product combining crosslinked hyaluronic acid derivatives with DNA fractions. The crosslinked HA provides enzyme resistance while the DNA fractions contribute to skin regeneration effects, achieving both reliability and functional benefits
Solution Approach 2:
The patent modifies the degree of crosslinking of hyaluronic acid to specific ranges (0.1-200% as weight ratio of crosslinking agent to HA monomer) to optimize both operational properties and enzyme resistance, balancing ease of operation with stability
2Productivity
If conventional hyaluronic acid fillers are used, then filling and cosmetic purposes are achieved, but skin regeneration effect is lacking
Solution Approach 1:
The patent merges crosslinked hyaluronic acid derivatives with DNA fractions in a specific weight ratio (7.0 to 9.5:0.5 to 3.0) to create a composite filler that provides both conventional cosmetic filling effects and additional skin regeneration functions through DNA-mediated extracellular matrix formation
Solution Approach 2:
The composite filler product achieves multiple functions simultaneously: tissue filling, wrinkle correction, and skin regeneration through DNA fraction stimulation of extracellular matrix formation, making it applicable for various cosmetic and therapeutic purposes
3Reliability
If crosslinked hyaluronic acid derivatives are used, then enzyme resistance is improved, but viscoelasticity may be compromised
Solution Approach 1:
The patent optimizes the degree of crosslinking within specific ranges (0.1-200% as weight ratio) to maintain adequate viscoelasticity while achieving sufficient enzyme resistance, balancing both properties through parameter control
Solution Approach 2:
The composite formulation with DNA fractions compensates for any viscoelasticity changes introduced by crosslinking, maintaining operational properties while achieving enhanced enzyme resistance
Data Source
Figure 1a
Figure 1b
Figure 1c
AI summary
The present invention refers to the injectable hyaluronic acid composition which is a crosslinked viscoelastic hyaluronic acid gel comprising DNA fractions. More particularly, it refers to the injectable hyaluronic acid composition comprising a hyaluronic acid composition crosslinked in the basic conditions with the degree of crosslinking between 0.1 and 200%, which is mixed with the DNA fractions of 0.1 to 50 wt%. The DNA fractions are selected, for example, from polynucleotide (PN) and polydeoxyribonucleotide (PDRN). The composition used for cosmetic purposes or therapeutic purposes, have improved viscoelastic rheological properties and enzyme resistance.